probenecid has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, W | 1 |
| Li, Y | 1 |
| Zhu, JY | 1 |
| Fang, D | 1 |
| Ding, HF | 1 |
| Dong, Z | 1 |
| Jing, Q | 1 |
| Su, SB | 1 |
| Huang, S | 1 |
1 other study available for probenecid and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Triple negative breast cancer development can be selectively suppressed by sustaining an elevated level of cellular cyclic AMP through simultaneously blocking its efflux and decomposition.
Topics: Animals; Cell Line, Tumor; Colforsin; Computational Biology; Cyclic AMP; Cyclic Nucleotide Phosphodi | 2016 |